{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:05Z","timestamp":1790820605522,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited or absent genetic counseling and testing resources in low- and medium-income countries lead to missed or late diagnoses for treatable metabolic conditions with irreversible complications. In some communities, misunderstanding about the etiology of a genetic condition may lead women whose children are affected to be viewed as a bad omen and become stigmatized or ostracized from their community. Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a lysosomal storage disorder in which deficiency or inactivity of the enzyme iduronate-2-sulfatase leads to accumulation of glycosaminoglycans throughout the body. The diagnosis can be made through clinical assessment, enzyme activity analysis, or DNA sequencing. Treatment requires a multidisciplinary approach combining supportive care with disease-modifying therapies, including enzyme replacement therapy where available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      To understand the incidence and impact of MPS II in Kenya, we sought to provide counseling and genetic testing to individuals and families with suspected MPS II. After pretest counseling, we collected blood from 25 individuals to determine iduronate-2-sulfatase levels and sequence the\n                      <jats:italic>IDS<\/jats:italic>\n                      gene. We identified a pathogenic or likely pathogenic variant in 17 of 25 individuals and subsequently identified 18 female carriers in these families. We catalog the genotype of males with MPS II and correlate this with the phenotypic profile of these individuals, the female carrier rate, and mortality within the families.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first summary of genotype\u2013phenotype correlations for MPS II in individuals from Kenya. These findings will allow the development of guidelines to identify individuals who may benefit from early evaluation, especially in those families where there is a risk of MPS II.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03881-3","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:33:48Z","timestamp":1762263228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges and opportunities with providing genetic testing and counseling for mucopolysaccharidosis type II in Kenya"],"prefix":"10.1186","volume":"20","author":[{"given":"Lucy N. Wainaina","family":"Mungai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Njeru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michuki","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syokau","family":"Ilovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth W.","family":"Nduati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Wamalwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Odongkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-8601","authenticated-orcid":false,"given":"Danny E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"12","key":"3881_CR1","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/s41436-018-0090-9","volume":"23","author":"A Zhong","year":"2021","unstructured":"Zhong A, Darren B, Loiseau B, He LQB, Chang T, Hill J, et al. Ethical, social, and cultural issues related to clinical genetic testing and counseling in low-and middle-income countries: a systematic review. Genet Med. 2021;23(12):2270\u201380.","journal-title":"Genet Med."},{"key":"3881_CR2","unstructured":"Health NI of. Precision Medicine Initiative (PMI) Working Group. The Precision Medicine Initiative Cohort Program\u2013Building a Research Foundation for 21st Century Medicine: Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH."},{"key":"3881_CR3","unstructured":"Canadian Association of Genetic Counsellors. What is a genetic counsellor? . https:\/\/www.cagc-accg.ca\/index.php?page=319. Accessed 2021"},{"key":"3881_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6939-14-41","volume":"14","author":"V Marsh","year":"2013","unstructured":"Marsh V, Kombe F, Fitzpatrick R, Williams TN, Parker M, Molyneux S. Consulting communities on feedback of genetic findings in international health research: sharing sickle cell disease and carrier information in coastal Kenya. BMC Med Ethics. 2013;14:1\u201313.","journal-title":"BMC Med Ethics"},{"key":"3881_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6939-10-13","volume":"10","author":"F Tekola","year":"2009","unstructured":"Tekola F, Bull S, Farsides B, Newport MJ, Adeyemo A, Rotimi CN, et al. Impact of social stigma on the process of obtaining informed consent for genetic research on podoconiosis: a qualitative study. BMC Med Ethics. 2009;10:1\u201310.","journal-title":"BMC Med Ethics"},{"key":"3881_CR6","unstructured":"Patrick Isika Muia NSM. Perceptions about death among the akamba in kibwezi division, makuenl district, kenya. http:\/\/erepository.uonbi.ac.ke\/bitstream\/handle\/11295\/20837\/Mula%20Patrick%20I_Perceptions%20About%20Death%20Among%20the%20Akamba%20in%20Kibwezi%20Division,%20Makuenl%20District,%20Kenya.pdf?sequence=3. Accessed 2003"},{"key":"3881_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10545-012-9533-7","volume":"36","author":"LM Pollard","year":"2013","unstructured":"Pollard LM, Jones JR, Wood TC. Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. J Inherit Metab Dis. 2013;36:179\u201387.","journal-title":"J Inherit Metab Dis."},{"key":"3881_CR8","first-page":"401","volume":"1","author":"H Amartino","year":"2014","unstructured":"Amartino H, Ceci R, Masllorens F, Gal A, Arberas C, Bay L, et al. Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome). Mol Genet Metab Rep. 2014;1:401\u20136.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"3881_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5114\/pedm.2021.109270","volume":"27","author":"L Spahiu","year":"2021","unstructured":"Spahiu L, Behluli E, Peterlin B, Nefic H, Hadziselimovic R, Liehr T, et al. Mucopolysaccharidosis III: molecular basis and treatment. Pediatr Endocrinol Diabetes Metab. 2021;27(3):199\u2013208. https:\/\/doi.org\/10.5114\/pedm.2021.109270.","journal-title":"Pediatr Endocrinol Diabetes Metab."},{"issue":"2","key":"3881_CR10","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1542\/peds.2007-1350","volume":"121","author":"R Martin","year":"2008","unstructured":"Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Mu\u00f1oz V, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377-86.","journal-title":"Pediatrics"},{"issue":"4","key":"3881_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/ijms21041258","volume":"21","author":"F D\u2019Avanzo","year":"2020","unstructured":"D\u2019Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020;21(4):1258.","journal-title":"Int J Mol Sci."},{"key":"3881_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:267\u201377.","journal-title":"Eur J Pediatr."},{"issue":"3","key":"3881_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejmg.2012.11.006","volume":"56","author":"RE Pi\u00f1a-Aguilar","year":"2013","unstructured":"Pi\u00f1a-Aguilar RE, Zaragoza-Ar\u00e9valo GR, Rau I, Gal A, Alc\u00e1ntara-Ortigoza MA, L\u00f3pez-Mart\u00ednez MS, et al. Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivation. Eur J Med Genet. 2013;56(3):159\u201362.","journal-title":"Eur J Med Genet."},{"key":"3881_CR14","unstructured":"Institute of Medical Genetics in Cardiff. The Human Gene Mutation Database. https:\/\/www.hgmd.cf.ac.uk\/ac\/index.php. Accessed 2023"},{"issue":"3","key":"3881_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227\u201340.","journal-title":"Mol Genet Metab."},{"key":"3881_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","volume":"96","author":"R Froissart","year":"2007","unstructured":"Froissart R, Da Silva IM, Maire I. Mucopolysaccharidosis type II: an update on mutation spectrum. Acta Paediatr. 2007;96:71\u20137.","journal-title":"Acta Paediatr."},{"key":"3881_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108392","volume":"788","author":"S Verma","year":"2021","unstructured":"Verma S, Pantoom S, Petters J, Pandey AK, Hermann A, Lukas J. A molecular genetics view on mucopolysaccharidosis Type II. Mutat Res\/Rev Mutat Res. 2021;788: 108392.","journal-title":"Mutat Res\/Rev Mutat Res."},{"key":"3881_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1651-2227.2002.tb03116.x","volume":"91","author":"R Froissart","year":"2002","unstructured":"Froissart R, Da Silva IM, Guffon N, Bozon D, Maire I. Mucopolysaccharidosis type II\u2013genotype\/phenotype aspects. Acta Paediatr. 2002;91:82\u20137.","journal-title":"Acta Paediatr."},{"issue":"3","key":"3881_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","volume":"118","author":"M Kosuga","year":"2016","unstructured":"Kosuga M, Mashima R, Hirakiyama A, Fuji N, Kumagai T, Seo JH, et al. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: genetic, pathological, and structural studies on iduronate-2-sulfatase. Mol Genet Metab. 2016;118(3):190\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.003.","journal-title":"Mol Genet Metab."},{"key":"3881_CR20","volume":"25","author":"Y Fukuhara","year":"2020","unstructured":"Fukuhara Y, Miura A, Yamazaki N, So T, Kosuga M, Yanagi K, et al. A cDNA analysis disclosed the discordance of genotype-phenotype correlation in a patient with attenuated MPS II and a 76-base deletion in the gene for iduronate-2-sulfatase. Mol Genet Metab Rep. 2020;25: 100692.","journal-title":"Mol Genet Metab Rep."},{"key":"3881_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa M, Alm\u00e1ssy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. https:\/\/doi.org\/10.1186\/1750-1172-6-72.","journal-title":"Orphanet J Rare Dis."},{"key":"3881_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","volume":"171","author":"BK Burton","year":"2012","unstructured":"Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr. 2012;171:631\u20139.","journal-title":"Eur J Pediatr."},{"issue":"6","key":"3881_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","volume":"19","author":"TA Burrow","year":"2007","unstructured":"Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution\/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007;19(6):628\u201335.","journal-title":"Curr Opin Pediatr."},{"issue":"8","key":"3881_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465\u201373.","journal-title":"Genet Med."},{"issue":"11","key":"3881_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","volume":"22","author":"KL McBride","year":"2020","unstructured":"McBride KL, Berry SA, Braverman N, Committee AT. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(11):1735\u201342.","journal-title":"Genet Med."},{"issue":"1","key":"3881_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase\u00ae Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99(1):18\u201325.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"3881_CR27","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","volume":"101","author":"A Tylki-Szymanska","year":"2012","unstructured":"Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr. 2012;101(1):e42-7.","journal-title":"Acta Paediatr."},{"issue":"6","key":"3881_CR28","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","volume":"124","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228-39.","journal-title":"Pediatrics"},{"issue":"7","key":"3881_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ijms17071065","volume":"17","author":"MF Coutinho","year":"2016","unstructured":"Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17(7):1065.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"3881_CR30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/ijms25042371","volume":"25","author":"M Malinowska","year":"2024","unstructured":"Malinowska M, Nowicka W, Kloska A, W\u0119grzyn G, Jak\u00f3bkiewicz-Banecka J. Efficacy of a combination therapy with laronidase and genistein in treating mucopolysaccharidosis type I in a mouse model. Int J Mol Sci. 2024;25(4):2371.","journal-title":"Int J Mol Sci."},{"issue":"7","key":"3881_CR31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","volume":"14","author":"E Piotrowska","year":"2006","unstructured":"Piotrowska E, Jakobkiewicz-Banecka J, Bara\u0144ska S, Tylki-Szyma\u0144ska A, Czartoryska B, W\u0119grzyn A, et al. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for Mucopolysaccharidoses. Eur J Hum Genet. 2006;14(7):846\u201352.","journal-title":"Eur J Hum Genet."},{"key":"3881_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13052-018-0565-y","volume":"44","author":"A Fraldi","year":"2018","unstructured":"Fraldi A, Serafini M, Sorrentino NC, Gentner B, Aiuti A, Bernardo ME. Gene therapy for Mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr. 2018;44:145\u201354.","journal-title":"Ital J Pediatr"},{"issue":"7","key":"3881_CR33","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/biomedicines12071523","volume":"12","author":"\u017b S\u0142yk","year":"2024","unstructured":"S\u0142yk \u017b, Stachowiak N, Ma\u0142ecki M. Recombinant adeno-associated virus vectors for gene therapy of the central nervous system: delivery routes and clinical aspects. Biomed. 2024;12(7):1523. https:\/\/doi.org\/10.3390\/biomedicines12071523.","journal-title":"Biomed."},{"issue":"1","key":"3881_CR34","first-page":"2328402","volume":"2021","author":"LN Mungai","year":"2021","unstructured":"Mungai LN, Njeru CM, Nyamai LA, Maina M. Mucopolysaccharidosis type II: a kenyan case series. Int J Endocrinol. 2021;2021(1):2328402.","journal-title":"Int J Endocrinol."},{"issue":"5","key":"3881_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz S, Bick D, Das S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet in Med. 2015;17(5):405\u201323.","journal-title":"Genet in Med."},{"key":"3881_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cca.2019.01.009","volume":"491","author":"W Zhang","year":"2019","unstructured":"Zhang W, Xie T, Sheng H, Shao Y, Lin Y, Jiang M, et al. Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type II: functional characterization of seven novel IDS variants. Clin Chim Acta. 2019;491:114\u201320.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"3881_CR37","first-page":"1014","volume":"52","author":"S Tomatsu","year":"2007","unstructured":"Tomatsu S, et al. High prevalence of the IDS allele containing Gly80 substitution in a Japanese population with mucopolysaccharidosis type II (Hunter syndrome) simultaneous frequent occurrence of two IDS alleles in a patient. J Hum Genet. 2007;52(11):1014\u201324.","journal-title":"J Hum Genet."},{"issue":"2","key":"3881_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ymgme.2013.08.011","volume":"111","author":"AC Brusius-Facchin","year":"2014","unstructured":"Brusius-Facchin AC, Schwartz IVD, Zimmer C, Ribeiro MG, Acosta AX, Horovitz D, et al. Mucopolysaccharidosis type II: identification of 30 novel mutations among latin American patients. Mol Genet Metab. 2014;111(2):133\u20138.","journal-title":"Mol Genet Metab."},{"key":"3881_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s004390050901","volume":"103","author":"S Karsten","year":"1998","unstructured":"Karsten S, Voskoboeva E, Tishkanina S, Pettersson U, Krasnopolskaja X, Bondeson ML. Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients. Hum Genet. 1998;103:732\u20135.","journal-title":"Hum Genet."},{"issue":"3","key":"3881_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2017-000415.PMID:29082022;PMCID:PMC5656182","volume":"2","author":"KIC Ong","year":"2017","unstructured":"Ong KIC, Kosugi H, Thoeun S, Araki H, Thandar MM, Iwagami M, Hongvanthong B, Brey PT, Kano S, Jimba M. Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond. BMJ Glob Health. 2017;2(3): e000415. https:\/\/doi.org\/10.1136\/bmjgh-2017-000415.PMID:29082022;PMCID:PMC5656182.","journal-title":"BMJ Glob Health"},{"key":"3881_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-017-0535-2","volume":"6","author":"A Zhong","year":"2017","unstructured":"Zhong A, Darren B, Dimaras H. Ethical, social and cultural issues related to clinical genetic testing and counseling in low-and middle-income countries: protocol for a systematic review. Systematic Rev. 2017;6:1\u20137.","journal-title":"Systematic Rev."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03881-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:34:12Z","timestamp":1762263252000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03881-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3881"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03881-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the KNH\/UoN research and ethics committee (PI40\/02\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"558"}}